BioNexus Gene Lab Corp. Operating Lease, Right-of-Use Asset, Amortization Expense
BioNexus Gene Lab Corp. (BGLC) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $31.19 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $15.60K, a 11.99% increase year-over-year.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $15.59K, a 16.52% increase year-over-year.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $14.77K, a 9.59% increase year-over-year.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $14.35K, a 3.06% decline year-over-year.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $56.43K, a 15.21% increase from fiscal 2024.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $48.98K, a 94.61% increase from fiscal 2023.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $25.17K, a 79.89% increase from fiscal 2022.
- BioNexus Gene Lab Corp. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $13.99K, a 17.37% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $31.19K 10-Q · filed 2026-08-14 | $45.96K derived: sum of 3 quarters · filed 2026-08-14 | $60.31K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $15.59K 10-Q · filed 2026-05-15 | $30.36K derived: sum of 2 quarters · filed 2026-05-15 | $44.71K derived: sum of 3 quarters · filed 2026-05-15 | $58.64K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $14.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $29.12K derived: sum of 2 quarters · filed 2026-04-14 | $43.05K derived: sum of 3 quarters · filed 2026-08-14 | $56.43K 10-K · filed 2026-04-14 |
| 2025-09-30 | $14.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $28.29K derived: sum of 2 quarters · filed 2026-08-14 | $41.67K 10-Q · filed 2025-11-14 | $55.14K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $13.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $27.31K 10-Q · filed 2026-08-14 | $40.79K derived: sum of 3 quarters · filed 2026-08-14 | $55.59K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $13.38K 10-Q · filed 2026-05-15 | $26.86K derived: sum of 2 quarters · filed 2026-05-15 | $41.66K derived: sum of 3 quarters · filed 2026-05-15 | $52.91K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $13.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $28.28K derived: sum of 2 quarters · filed 2026-04-14 | $39.53K derived: sum of 3 quarters · filed 2026-04-14 | $48.98K 10-K · filed 2026-04-14 |
| 2024-09-30 | $14.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $26.06K derived: sum of 2 quarters · filed 2025-11-14 | $35.51K 10-Q · filed 2025-11-14 | $45.06K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $11.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $20.70K 10-Q · filed 2025-08-18 | $30.25K derived: sum of 3 quarters · filed 2025-08-18 | $37.98K derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $9.45K 10-Q · filed 2025-05-15 | $19.00K derived: sum of 2 quarters · filed 2025-05-15 | $26.73K derived: sum of 3 quarters · filed 2025-05-15 | $30.65K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $9.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $17.28K derived: sum of 2 quarters · filed 2025-04-15 | $21.20K derived: sum of 3 quarters · filed 2025-04-15 | $25.17K 10-K · filed 2025-04-15 |
| 2023-09-30 | $7.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $11.65K derived: sum of 2 quarters · filed 2024-11-15 | $15.62K 10-Q · filed 2024-11-15 | $16.86K derived: sum of 4 quarters · filed 2024-11-15 |
| 2023-06-30 | $3.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $7.89K 10-Q · filed 2024-08-14 | $9.13K derived: sum of 3 quarters · filed 2024-08-14 | $13.30K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $3.97K 10-Q · filed 2024-05-15 | $5.21K derived: sum of 2 quarters · filed 2024-05-15 | $9.38K derived: sum of 3 quarters · filed 2024-05-15 | $13.62K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.24K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | $5.41K derived: sum of 2 quarters · filed 2024-04-16 | $9.65K derived: sum of 3 quarters · filed 2024-04-16 | $13.99K 10-K · filed 2024-04-16 |
| 2022-09-30 | $4.17K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | $8.41K derived: sum of 2 quarters · filed 2024-03-26 | $12.75K 10-Q/A · filed 2024-03-26 | |
| 2022-06-30 | $4.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | $8.59K 10-Q · filed 2023-08-16 | ||
| 2022-03-31 | $4.34K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $16.93K 10-K · filed 2023-03-31 | |||
| 2021-06-30 | $4.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $8.86K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $4.43K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $10.82K 10-K · filed 2022-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |